ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report highlights its specialty chemicals operations and ESG metrics.
Tatva Chintan Pharma Chem Limited has submitted its Annual Report for the financial year 2025-26. The company's 30th Annual General Meeting is scheduled for September 25, 2026.
Tatva Chintan Pharma Chem Limited has scheduled its 30th Annual General Meeting for September 25, 2026. Key agenda items include dividend declaration and director re-appointments.
Tatva Chintan Pharma Chem Limited scheduled its 30th AGM for September 25, 2026. Key agenda items include dividend declaration and increasing borrowing limits to ₹1,000 Crore.
Tatva Chintan Pharma Chem announced the resignation of Mr. Ajay Rawat, Assistant Vice President – Research and Development, effective from November 13, 2026.
Tatva Chintan Pharma Chem Limited is communicating the process for TDS on the final dividend for FY 2025-26 to its shareholders. Shareholders are required to submit necessary tax declarations by 10 September 2026.